Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,477 Cr revenue.
COGS 39.8%, employees 18.4%.
“total income was INR $5.”
“EBITDA stood at INR 156.”
“FY 'twenty six will be a year of strong growth on a base of FY 'twenty four, not FY 'twenty five.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 11.1%▲ | 10.5% |
| ROCE | 13.8%▼ | 13.8% |
| Net Margin | 11.2%▲ | 8.7% |
| EBITDA Margin | 21.5%▲ | 16.0% |
| Debt To Equity | 0.10x▼ | 0.21x |
| Rev Growth 3yr | 16.3%▲ | 5.8% |
| EPS Growth 3yr | 59.7%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,575 Cr +6.7% | ₹1,477 Cr -5.2% | ₹1,559 Cr +30.8% | ₹1,191 Cr +25.2% | ₹951 Cr +1.5% | ₹937 Cr +22.8% | ₹763 Cr +14.4% | ₹667 Cr |
| Other Income | ₹25 Cr +22.7% | ₹21 Cr +63.5% | ₹13 Cr +28.7% | ₹10 Cr +369.4% | ₹2 Cr -87.1% | ₹16 Cr +314.2% | ₹4 Cr +11.3% | ₹3 Cr |
| Total Income | ₹1,600 Cr +6.9% | ₹1,497 Cr -4.7% | ₹1,571 Cr +30.8% | ₹1,201 Cr +26.0% | ₹953 Cr +0.0% | ₹953 Cr +24.3% | ₹767 Cr +14.4% | ₹670 Cr |
| COGS | ₹613 Cr +4.3% | ₹588 Cr +1.8% | ₹577 Cr +20.7% | ₹478 Cr +13.3% | ₹422 Cr -3.7% | ₹438 Cr +15.3% | ₹380 Cr +3.8% | ₹366 Cr |
| ₹1,359 Cr +10.8% | ₹1,227 Cr +4.9% | ₹1,170 Cr +18.7% | ₹985 Cr +13.1% | ₹871 Cr +2.8% | ₹848 Cr +18.8% | ₹714 Cr +9.8% | ₹650 Cr | |
| Profit Before Tax | ₹241 Cr -30.5% | ₹346 Cr -13.7% | ₹401 Cr +86.1% | ₹216 Cr +162.6% | ₹82 Cr -22.0% | ₹105 Cr +99.0% | ₹53 Cr +160.2% | ₹20 Cr |
| Exceptional Items | ₹0.00 Cr -100.0% | ₹76 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹62 Cr -28.5% | ₹86 Cr -14.9% | ₹101 Cr +94.1% | ₹52 Cr +184.8% | ₹18 Cr -25.8% | ₹25 Cr -32.7% | ₹37 Cr +842.4% | ₹4 Cr | |
| Net Profit | ₹179 Cr -31.1% | ₹260 Cr -13.3% | ₹300 Cr +83.5% | ₹164 Cr +156.2% | ₹64 Cr -20.8% | ₹81 Cr +397.4% | ₹16 Cr -1.4% | ₹16 Cr |
| Profit (Owners) | ₹179 Cr -31.1% | ₹260 Cr -13.3% | ₹300 Cr +83.5% | ₹164 Cr +156.2% | ₹64 Cr -20.8% | ₹81 Cr +397.4% | ₹16 Cr -1.4% | ₹16 Cr |
| Other Comprehensive Income | ₹0.03 Cr ↑ Recovery | (₹0.04 Cr) ↓ Decline | ₹1 Cr ↑ Recovery | (₹4 Cr) +40.9% | (₹6 Cr) -279.0% | (₹2 Cr) -260.5% | (₹0.43 Cr) ↓ Decline | ₹0.32 Cr |
| EPS | ₹139.61 | ₹202.74 | ₹233.89 | ₹127.45 | ₹49.74 | ₹62.85 | ₹12.63 | ₹12.82 |
| Diluted Shares | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Intimation about Schedule of Analyst / Institutional Investor Meeting on June 11, 2026
Intimation about Schedule of Analyst / Institutional Investor Meeting on June 8 & 9, 2026
Neuland Laboratories Limited has informed the Exchange about Schedule of meet on May 28, 2026
Transcript of the Earnings Call conducted on May 12, 2026
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Neuland Laboratories Limited has informed the Exchange about Investor Presentation
Neuland Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Press Release on the Financial Results of the Company for the quarter and year ended March ...
Audited Financial Results and recommendation of final dividend for financial year 2025-26
Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2025-26
Q4FY26 Earnings Call Intimation
Newspaper Publication of Notice for transferring unclaimed dividend and underlying equity shares to IEPF
Neuland Laboratories Limited has informed the Exchange about Loss of Share Certificates
Neuland Laboratories Limited has informed the Exchange about Loss of Share Certificates
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication